전체 8345
-
- Melanoma: Whats Beyond Mutant BRAF? (NIH Only)
-
- - Jeffrey A. Sosman, M.D., Vanderbilt-Ingram Cancer Center (2010/11/18)
- - Category : NCI CCR Grand Rounds (NIH Only)
- Dr. Sosman received his M.D., from Albert Einstein College of Medicine in the Bronx, NY, and completed his internship in internal medicine and residency in anatomic pathology at the University of Chicago Hospital in Chicago, IL. He then served as a resident in internal medicine at the University of Wisconsin Hospital and Clinics in Madison, WI, which was followed by clinical and research fellowships in human oncology at University of Wisconsin Cancer Center in Madison. Between 1989 and 1995, Dr. Sosman served first as an assistant professor and then associate professor of medicine in the Hematology/Oncology Department at Loyola University Stritch School of Medicine in Maywood, IL. He then served as an associate professor and later the director of clinical research at the University of Illinois at Chicago College of Medicine before joining the Division of Hematology/Oncology at Vanderbilt-Ingram Cancer Center (VICC), where he is currently employed. Dr. Sosman？？？s interests center on the targeted and anti-angiogenic-based therapy of melanoma and renal cancer. He is co leader of VICC？？？s new Personalized Cancer Medicine Initiative, one of the first centers in the nation to offer cancer patients routine DNA-level genotyping of their cancerous tumors to help identify and treat the genetic mutations linked to their cancer. His abilities as both researcher and physician place him among a rare group of individuals who can drive developments in this field into treatments？？？and ultimately cures. He has authored more than 100 peer-reviewed articles and is on the editorial boards of Clinical Cancer Research and the Journal of Clinical
NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. CME credit available via sign-up sheets in the lecture hall and at designated video-bridge sites only. NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. CME credit available via sign-up sheets in the lecture hall and at designated video-bridge sites only.
Melanoma: Whats Beyond Mutant BRAF? (NIH Only)
-
- National Science Advisory Board for Biosecurity (NSABB) - October 2010
-
- - NIH Office of Biotechnology Activities (2010/11/18)
- - Category : National Science Advisory Board for Biosecurity
- The NSABB was established to advise on oversight of dual use life sciences research, defined as biological research that generates information and technologies that could be misused to pose a biological threat to public health and other aspects of national security. The October 19 meeting will focus on an update of Federal activities relevant to the mission of the NSABB; activities of five NSABB Working Groups; consideration of advances in synthetic biology in relation to NSABB recommendations regarding biosecurity concerns raised in this field; and, planning for future NSABB meetings and activities.
National Science Advisory Board for Biosecurity (NSABB) - October 2010
-
- Expansion of Good but Elimination of Bad Stem Cells
-
- - Linheng Li, Ph.D., University of Kansas Medical Center (2010/11/18)
- - Category : Stem Cell
- The Stem Cell Interest Group was established to enhance communication and to foster collaboration among scientists from varying disciplines interested in stem cells. Topics of interest include fundamental stem cell biology, ontogeny, gerontology, and the therapeutic potential of stem cells. The SCIG serves as an open forum for discussion and dissemination of knowledge about all aspects of stem cell biology
For more information, visit
http://www.stowers-institute.org/labs/LiLab.asp
http://sigs.nih.gov/scig/Pages/default.aspx
Expansion of Good but Elimination of Bad Stem Cells
-
- Redox Biology: Angiogenesis and Cancer Therapy
-
- - D. Roberts and J. Mitchell (2010/11/18)
- - Category : Redox Biology
- For more information, visit
http://ccr.cancer.gov/careers/courses/rb/
Redox Biology: Angiogenesis and Cancer Therapy
-
- Comparative Effectiveness and Personalized Medicine: An Essential Interface (Day 2)
-
- - National Institutes of Health, Agency for Healthcare Research and Quality, ECRI Institute (2010/11/18)
- - Category : Conferences
- A conference on the status of comparative effectiveness research and its use in policy and practice.
The senior leadership of ECRI Institute1, NIH, AHRQ, the Kaiser Permanente Institute for Health Policy, Health Affairs, the Milbank Memorial Fund, and the Leonard Davis Institute of Health Economics at the University of Pennsylvania invite you to a major conference on the interface between personalized medicine and comparative effectiveness research. This meeting will be convened on October 19th and 20th, 2010, on the campus of the National Institutes of Health in Bethesda, Maryland.
Drs. Francis Collins, Director of NIH, and Carolyn Clancy, Director of AHRQ, are among our many distinguished presenters. The conference sessions, over a day and a half, are designed to be understandable and useful to a range of healthcare constituencies. The agenda will have significant time devoted to dialog with the audience and for you to meet the speakers.
With the advent of healthcare reform, our nation will be embarking on an unprecedented effort to determine which health care intervention works best for the treatment of a given condition or disorder. The Patient Protection and Affordable Care Act emphasizes the importance of comparative effectiveness research in order to evaluate clinical outcomes across study populations. It also acknowledges the key role of personalized medicine in ensuring the capacity to identify both individual and subgroup differences within populations. The addition of personalized medicine will help clinicians and patients better predict which intervention will deliver the optimal treatment to the appropriate patient at the right time.
This meeting explores two critical streams of scientific inquiry in order to better align evidentiary, infrastructure and database needs, to highlight research challenges, and to brainstorm about regulatory, ethical and societal factors affecting both fields. Our aim is to forge new synergies capable of generating innovation in the course of healthcare reform which will result in enhanced health outcomes for the American people.
Comparative Effectiveness and Personalized Medicine: An Essential Interface (Day 2)
-
- Risks and Benefits and Research with Children - 2010 (Session 5)
-
- - Dave Wendler and Robert Nelson (2010/11/18)
- - Category : Bioethics
- Ethical and Regulatory Aspects of Clinical Research
Course Objectives
By the end of this course, participants will be able to:
Utilize a systematic framework for evaluating the ethics of a clinical research protocol.
Apply appropriate codes, regulations, and other documents governing the ethical conduct of human subject research to their own research.
Discuss controversial issues relating to human subject research, including Phase 1 research, randomization, children in research, international research, etc.
Identify the critical elements of informed consent and strategies for implementing informed consent for clinical research.
Describe the purpose, function, and challenges of IRBs.
Appreciate the experience of human subjects who have participated in research protocols.
For more information, visit
http://www.bioethics.nih.gov/hsrc/index.shtml
Risks and Benefits and Research with Children - 2010 (Session 5)
-
- Ethics Rounds: What Defines Death?
-
- - James Bernat, Jefferson McMahan and Robert M. Veatch (2010/11/18)
- - Category : Clinical Center Grand Rounds
- CC Grand Rounds
(1) James Bernat, MD, Professor of Neurology and Medicine, Dartmouth Medical School, and Director, Program in Clinical Ethics, Dartmouth-Hitchcock Medical Center
(2) Jefferson McMahan, PhD, Professor of Philosophy, Rutgers University
(3) Robert M. Veatch, PhD, Professor of Medical Ethics, Kennedy Institute of Ethics, Georgetown University
Ethics Rounds: What Defines Death?
-
- "Measuring and Modeling Life-Death Decisions in Single Cells"
-
- - Dr. Peter Sorger, Harvard Medical School (2010/11/18)
- - Category : Wednesday Afternoon Lectures
- Lecture Summary:
When monitoring signal transduction at the level of single living cells, we observe remarkably complex dynamics and great variability from one cell to the next. However, it is also clear that finely tuned interactions among processes operating on quite different time scales are essential in cell fate determination and, conversely, that errors in coordination underlie many oncogenic changes. How can the observed variability among genetically identical cells be reconciled with an apparent requirement for precise control, what is the impact of variability on the evolution of tumors and what are the implications for emergence of drug resistant cancers in patients?
I will begin to address these issues with an emphasis on cellular responses to TRAIL, a prototypical inducer of receptor-mediated (extrinsic) apoptosis and an investigational therapeutic. Some TRAIL-treated human cells die within ~40 min, some only after 12 hr, and yet others live indefinitely. We have explored three explanations for these differences: (i) genetic or epigenetic variation (ii) the involvement of one or more biochemical processes subject to stochastic fluctuation (iii) transient but deterministic differences in cell state. I will illustrate how all three interact on different time scales to determine those aspects of cellular physiology that are highly invariant and those that are variable. I will also illustrate how studying these problems requires mathematical analysis of the underlying biochemistry. This analysis involves a close interplay between model generation, model calibration against data and model verification through empirical testing of molecular hypotheses. I will advance the thesis that we must replace the informal pictorial models currently dominating molecular biology with probabilistic mathematical constructs that assign rigorous ？？？degrees of belief？？？ to specific biochemical hypothesis given prior knowledge and a specific set of empirical data.
Lecture Objectives:
1. To describe an approach to understanding signal transduction pathways that involves combining biochemical and cell-based measurement with mathematical modeling of relevant molecular processes. In my lecture the focus will be on receptor-mediated cell death triggered by TRAIL and Fas ligands
2. To present an analysis of variability from one cell to the next in responses to TRAIL and our determination that this variability has a non-genetic basis, arising from natural fluctuations in protein levels among otherwise non-identical cells.
3. To consider the impact of non-genetic variability on responses to therapeutic drugs more generally and on the likely connection between variability and fractional killing observed clinically. To advance the idea that non-genetic variability, having its origins in the inherently stochastic nature of biochemical reactions, is a probable explanation for many phenomena currently ascribed to tumor stem cells.
The NIH Directors Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
"Measuring and Modeling Life-Death Decisions in Single Cells"
-
- Induction and Regulation of T Helper Effector Responses in Parasitic Infection
-
- - Dragana Jankovic, NIAID; NIH (2010/11/18)
- - Category : Immunology
Induction and Regulation of T Helper Effector Responses in Parasitic Infection
-
- The Interagency Autism Coordinating Committee - October 2010
-
- - Thomas Insel, M.D. (2010/11/18)
- - Category : Interagency Autism Coordinating Committee
- Meeting of the IACC Committee
The Interagency Autism Coordinating Committee - October 2010
-
- Mapping the Building Blocks of Life, and a Global View on Protein Expression in Normal and Cancer Tissues
-
- - Mathias Uhlen (2010/11/18)
- - Category : Special
- Prof. Mathias Uhlén Addresses the Role of Protein Expression on the Human Protein Atlas
Mapping the Building Blocks of Life, and a Global View on Protein Expression in Normal and Cancer Tissues
-
- Mouse Genetic Models of Autism-Related Traits: How Do We Know When We Have One?
-
- - Richard E. Paylor, PhD, Baylor College of Medicine (2010/11/18)
- - Category : Neuroscience
- Dr. Paylor is a leader in developing and implementing behavioral test batteries for the analysis of mutant mice. In particular, he is well recognized for his research directed towards the behavioral characterization of mouse genetic models of neurodevelopmental disorders including Fragile X, Williams-Beuren, Rett, DiGeorge, and Smith-Magenis syndromes. New findings from his lab have shown that both pharmacological and genetic manipulations can alter several behavioral responses in the mouse model of Fragile X. Dr. Paylor has also identified a novel transgenic mouse model with unique molecular alterations resulting in multiple autistic-like traits. Recently, Dr. Paylor？？？s lab has initiated a project with the long-term goal to employ the R6/2 transgenic mice to identify putative genetic/molecular modifiers of Huntington？？？s Disease, which could lead to potential targets for therapeutic intervention.
NIH Neuroscience Seminar Series
Mouse Genetic Models of Autism-Related Traits: How Do We Know When We Have One?
-
- TRACO: Prostate Cancer and Radiation Oncology
-
- - W. Dahut and K. Camphausen (2010/11/18)
- - Category : TRACO
- For more information, visit
http://ccr.cancer.gov/careers/traco.asp
TRACO: Prostate Cancer and Radiation Oncology
-
- Rapamycin Resistant T Cells: Biology and Clinical Application (NIH Only)
-
- - Daniel H. Fowler, M.D., Center for Cancer Research, NCI (2010/11/18)
- - Category : NCI CCR Grand Rounds (NIH Only)
- Dr. Fowler completed medical school and his residency at Wayne State University. He then completed Medical Oncology training at NCI in 1991. After a research fellowship in the NCI Experimental Immunology Branch, he returned to NCIs former Medicine Branch in 1995. In 1996, Dr. Fowler received the Translational Research Award from the Leukemia Society of America to develop approaches to allograft engineering using Th1/Th2 subsets. In 2007, he became a member of the American Society of Clinical Investigation. His current research utilizes animal models and pilot clinical trials to evaluate the role of ex vivo expanded donor T cells that are generated in the presence of the immune modulation drug rapamycin. This research has demonstrated that murine and human T cell polarization toward differential cytokine secreting subsets (Th1 and Th2) is maintained during rapamycin exposure. Such rapamycin resistant T cells mediate increased in vivo effects upon adoptive transfer; this increased efficacy is primarily attributable to an anti-apoptotic phenotype that results in increased T cell survival post-infusion. The primary clinical application for this research to date has been in the setting of low-intensity allogeneic hematopoietic stem cell transplantation, where infusion of rapamycin resistant T cells appears to safely promote alloengraftment.
NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. CME credit available via sign-up sheets in the lecture hall and at designated video-bridge sites only.
Rapamycin Resistant T Cells: Biology and Clinical Application (NIH Only)
-
- ASA All-Hands Meeting - October 2010 (HHS Only)
-
- - Dr. Thomas Frieden, CDC Director (2010/11/18)
- - Category : HHS Only
- First ASA All-Hands meeting of the Fiscal Year
ASA All-Hands Meeting - October 2010 (HHS Only)
-
- Redox Biology:"Contribution of Oxidative Stress to Human Cancer Evidence from Cancer Epidemiology and Oxidative Stress Tissue Injury"
-
- - S. Ambs and P. Pacher (2010/11/18)
- - Category : Redox Biology
- For more information, visit
http://ccr.cancer.gov/careers/courses/rb/
Redox Biology:"Contribution of Oxidative Stress to Human Cancer Evidence from Cancer Epidemiology and Oxidative Stress Tissue Injury"
-
- NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy For Premature Infants - Day 1
-
- - NICHD and OMAR (2010/11/18)
- - Category : Conferences
- Babies born before the 28th week of pregnancy？？？more than 30,000 per year in the United States？？？are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. FDA in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks？？？ gestation. The National Institutes of Health is convening a Consensus Development Conference October 27-29, 2010 to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants.
NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy For Premature Infants - Day 1
-
- Ethics of International Research - 2010 (Session 6)
-
- - Alan Wertheimer, Seema Shah and Joe Millum (2010/11/18)
- - Category : Bioethics
- Ethical and Regulatory Aspects of Clinical Research
Course Objectives
By the end of this course, participants will be able to:
Utilize a systematic framework for evaluating the ethics of a clinical research protocol.
Apply appropriate codes, regulations, and other documents governing the ethical conduct of human subject research to their own research.
Discuss controversial issues relating to human subject research, including Phase 1 research, randomization, children in research, international research, etc.
Identify the critical elements of informed consent and strategies for implementing informed consent for clinical research.
Describe the purpose, function, and challenges of IRBs.
Appreciate the experience of human subjects who have participated in research protocols.
For more information, visit
http://www.bioethics.nih.gov/hsrc/index.shtml
Ethics of International Research - 2010 (Session 6)
-
- The Evolution of PET: Images of Progress
-
- - Carolyn Cidis Meltzer, MD, Emory University School of Medicine (2010/11/18)
- - Category : Clinical Center Grand Rounds
- CC Grand Rounds
John Doppman Memorial Lecture for Imaging Sciences
The Evolution of PET: Images of Progress
-
- Epigenetic Genome Control by Heterochromatin and RNAi Machinery
-
- - Dr. Shiv Grewal, Center for Cancer Research, National Cancer Institute (2010/11/18)
- - Category : Wednesday Afternoon Lectures
- Lecture Summary:
Expression profiling of eukaryotic genomes has revealed widespread transcription outside the confines of protein-coding genes, leading to the production of antisense and non-coding RNAs. Studies in Schizosaccharomyces pombe and multicellular organisms suggest that transcription and non-coding RNAs provide a framework for the assembly of heterochromatin structures, which have been linked to various chromosomal processes. In addition to gene regulation, heterochromatin is critical for centromere function, cell fate determination as well as transcriptional and posttranscriptional silencing of repetitive DNA elements that are known to be major source of genomic instability. We have found that heterochromatin factors are widely distributed across euchromatic loci and collaborate with RNAi machinery to suppress antisense transcripts across large portions of the genome. Our recent progress in understanding the mechanisms of heterochromatin assembly, and the roles of RNAi and heterochromatin factors in epigenetic genome control will be discussed.
Lecture Objectives:
1. Discuss roles of RNAi machinery and non-coding RNAs in heterochromatin assembly.
2. Roles of heterochromatin machinery in gene silencing and maintenance of genome stability.
3. Novel genome surveillance mechanisms essential for silencing retrotransposons.
The NIH Directors Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Epigenetic Genome Control by Heterochromatin and RNAi Machinery